Skip to main content
大禹生物 logo

大禹生物 — Investor Relations & Filings

Ticker · 920970 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 384 across all filing types
Latest filing 2023-03-19 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920970

About 大禹生物

http://www.sxdysw.cn/

Shanxi Dayu Biological Assistance Co., Ltd. specializes in the research, development, and production of advanced animal nutrition and health solutions. The company focuses on the manufacturing of feed additives, micro-ecological preparations, and biological feed products. Its core portfolio includes probiotics, enzyme preparations, and functional premixes designed to enhance livestock immunity, improve feed conversion rates, and promote sustainable farming practices. By leveraging biotechnology, the firm provides integrated solutions for the aquaculture and animal husbandry sectors, emphasizing scientific innovation and product quality to support the modernization of the agricultural supply chain.

Recent filings

Filing Released Lang Actions
高级管理人员辞职公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management personnel, specifically the general manager, including details about the resignation date, shareholding, and impact on the company. It does not contain financial data, audit information, or report content. It is clearly about management changes, fitting the category of Board/Management Information (MANG). The document length is short and focused solely on management changes, not a report or announcement of a report publication.
2023-03-19 Chinese
董事辞职公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of two company directors, including details about their shareholdings, resignation reasons, and the impact on the company's board composition. It does not contain financial data, audit information, or report content. It is clearly about changes in the company's board of directors. Therefore, it fits the category of Board/Management Information (MANG). The document length and content confirm it is not a brief notice or a report publication announcement but a formal announcement of management changes.
2023-03-19 Chinese
2022年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2022 Annual Performance Express Report" and contains preliminary financial data for the year 2022, including revenue, net profit, earnings per share, and asset figures. It explicitly states that the data are preliminary and unaudited, with final audited figures to be disclosed in the 2022 Annual Report. The document is relatively short (2006 characters) and serves as a quick earnings update rather than a full comprehensive report. It includes management commentary on performance drivers and risks but lacks full audited financial statements or detailed analysis typical of an Annual Report (10-K) or Interim Report (IR). This type of document is best classified as an Earnings Release (ER), which provides initial quarterly or annual financial highlights without the full detail of an annual report. FY 2022
2023-02-26 Chinese
2022年年度业绩预告公告
Earnings Release Classification · 95% confidence The document is a 2022 annual performance forecast announcement by Shanxi Dayu Biological Engineering Co., Ltd. It provides preliminary financial data for the full year 2022, explicitly stating that the data is unaudited and subject to the final annual report. The document is short (831 characters) and serves as a forecast or preliminary notice rather than the full annual report itself. It also includes a risk warning advising investors to wait for the official annual report. This fits the profile of an Earnings Release (ER) as it announces key financial results highlights for the year but is not the full audited Annual Report (10-K). FY 2022
2023-02-26 Chinese
稳定股价措施实施结果公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the implementation results of a stock repurchase (share buyback) plan by the company 山西大禹生物工程股份有限公司. It details the number of shares repurchased, the funds used, the timeline, and compliance with regulations. There is no financial statement or comprehensive report content, but rather a disclosure of the share repurchase activity and its results. This fits the category of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares.
2023-02-07 Chinese
股票解除限售公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the lifting of stock trading restrictions (解除限售公告) for certain shareholders, detailing the number of shares becoming tradable, the shareholders involved, and the reasons for lifting the restrictions. It includes tables showing shareholding changes and confirms no violations or commitments outstanding. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about share capital status changes, specifically about lifting share lock-up restrictions, which fits best under Share Issue/Capital Change (SHA) category rather than a full financial report or other categories.
2022-12-08 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.